Navigation Links
SRI International Licenses Bed Bug Detection Technology to Redcoat, a Virginia-Based Start-Up Company
Date:3/19/2013

MENLO PARK, Calif, March 19, 2013 /PRNewswire/ -- SRI International has licensed its proprietary bed bug detection technology to Redcoat Solutions, Inc., a new company focused on developing products to detect and treat insect infestations.  Redcoat is located in Harrisonburg, VA, where SRI has a research center.

Scientists at SRI developed a rapid, sensitive test that recognizes molecules specific to bed bugs. Redcoat intends to market the device under the brand name RAPID PURSUIT™. Based on preliminary testing, RAPID PURSUIT presents a number of advantages: unlike other detection devices, the test requires no sophisticated equipment and registers a response in minutes, and RAPID PURSUIT is designed to detect only bedbugs, avoiding confusion that could be caused by the presence of other pests.

Current bed bug detection methods and products do not have the effectiveness, ease of use, affordability, and stealth of RAPID PURSUIT. Glue traps and devices that use attractants such as carbon dioxide require that a bed bug actually come into contact with the device. Visual inspection is estimated to be only 30 percent accurate.  Canine inspection, while often accurate, can be expensive and indiscreet. 

RAPID PURSUIT eliminates the need to see or handle actual bed bugs, because it detects the residue – or "footprints" – that the bugs leave behind.  It will be a powerful tool for pest control companies, hotel operators, and international travelers, among many other types of users.   

"Solving the bed bug infestation problem is a critical need for the hospitality industry and is a real battle for people living in cities in America and throughout the world," said Krishna Kodukula , Ph.D., executive director for Strategic Development, SRI Biosciences. "We are proud that research from SRI Shenandoah Valley has led to the development of a new product to help curb pest infestations.  We have the ideal partner in Redcoat."

Redcoat Solutions, Inc.'s Chief Executive Officer, John Hall , has drawn upon his knowledge of the bed bug detection and treatment industry in guiding the company toward the upcoming launch of RAPID PURSUIT.  "We have assembled an excellent management team, and we have worked closely with SRI to develop a great product that will revolutionize bed bug detection in several industries," said Hall.  "We look forward to taking RAPID PURSUIT to market very soon, and we already are at work on new products that we will introduce over the next several months.  Redcoat has a great business opportunity, and one of the best things is that it will be based right here in the Shenandoah Valley."

About SRI's Biosciences Division
SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from initial discoveries to the start of human clinical trials. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.


'/>"/>
SOURCE SRI International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SOTIO a.s. Appoints Chiltern International
2. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
3. La Société Internationale dUrologie lanza la SIU Academy, un nuevo recurso para urólogos
4. Abacus International Expands Annual Partnership With HealthEconomics.Com
5. Dyadic International To Present At World Biofuels Markets
6. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
7. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
8. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
9. Chicago to Welcome Data Science, Big Data and Data Mining Leaders at the 19th International ACM Knowledge Discovery and Data Mining Conference, KDD 2013
10. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
11. German Academic Exchange Service funds international project on spintronics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):